Wendy Stock

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. doi request reprint Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802
    Wendy Stock
    University of Chicago, Illinois, USA
    Cancer 119:90-8. 2013
  2. ncbi request reprint Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples
    Wendy Stock
    University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Int J Oncol 28:1099-103. 2006
  3. pmc What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
    Wendy Stock
    Section of Hematology Oncology, Department of Medicine, University of Chicago and University of Chicago Cancer Research Center, IL 60637, USA
    Blood 112:1646-54. 2008
  4. doi request reprint Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Wendy Stock
    Department of Medicine, Section of Hematology and Oncology, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637 1463, USA
    Leuk Lymphoma 51:188-98. 2010
  5. doi request reprint Adolescents and young adults with acute lymphoblastic leukemia
    Wendy Stock
    University of Chicago, Medical Center, Chicago, IL 60637, USA
    Hematology Am Soc Hematol Educ Program 2010:21-9. 2010
  6. doi request reprint A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
    Wendy Stock
    Section of Hematology Oncology, University of Chicago Cancer Research Center, 5841 S Maryland, M C 2115, Chicago, IL 60637, USA
    Invest New Drugs 26:331-8. 2008
  7. pmc Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Biol Blood Marrow Transplant 18:913-21. 2012
  8. doi request reprint Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 50:1809-17. 2009
  9. pmc Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions
    Hongtao Liu
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Blood 118:6438-45. 2011
  10. doi request reprint High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML)
    Sarah M Larson
    Section of Hematology Oncology, University of Chicago Hospitals, Chicago, IL 60637, USA
    Leuk Lymphoma 53:445-50. 2012

Detail Information

Publications50

  1. doi request reprint Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802
    Wendy Stock
    University of Chicago, Illinois, USA
    Cancer 119:90-8. 2013
    ....
  2. ncbi request reprint Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples
    Wendy Stock
    University of Chicago Cancer Research Center, Chicago, IL 60637, USA
    Int J Oncol 28:1099-103. 2006
    ..Based on these results, we caution against interchanging BM with PB sampling for MRD monitoring during treatment of CML since this may lead to misinterpretation of treatment results...
  3. pmc What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
    Wendy Stock
    Section of Hematology Oncology, Department of Medicine, University of Chicago and University of Chicago Cancer Research Center, IL 60637, USA
    Blood 112:1646-54. 2008
    ..Based on these observations, a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated...
  4. doi request reprint Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Wendy Stock
    Department of Medicine, Section of Hematology and Oncology, University of Chicago and University of Chicago Cancer Research Center, Chicago, IL 60637 1463, USA
    Leuk Lymphoma 51:188-98. 2010
    ..Other TKI-based therapies are also showing potential in imatinib-resistant disease. This article reviews current and emerging treatments in Ph+ ALL...
  5. doi request reprint Adolescents and young adults with acute lymphoblastic leukemia
    Wendy Stock
    University of Chicago, Medical Center, Chicago, IL 60637, USA
    Hematology Am Soc Hematol Educ Program 2010:21-9. 2010
    ..These trials have been designed to provide important new clinical, psychosocial, and biological insights, and to further improve the survival of this challenging and unique group of patients...
  6. doi request reprint A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia
    Wendy Stock
    Section of Hematology Oncology, University of Chicago Cancer Research Center, 5841 S Maryland, M C 2115, Chicago, IL 60637, USA
    Invest New Drugs 26:331-8. 2008
    ..No correlation was observed between the development of DLT and pharmacokinetics. The RTPD is 1,750 mg. XK469R induced hematological responses in patients with refractory leukemia at tolerable doses...
  7. pmc Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Biol Blood Marrow Transplant 18:913-21. 2012
    ..Clofarabine-melphalan-alemtuzumab conditioning yields promising response and duration of response, but renal toxicity poses a considerable risk particularly in older patients...
  8. doi request reprint Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence
    Koen Van Besien
    Section of Hematology Oncology, University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 50:1809-17. 2009
    ..The high incidence of MDC after alemtuzumab containing conditioning contributes to the low risk of acute and chronic GVHD...
  9. pmc Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions
    Hongtao Liu
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA
    Blood 118:6438-45. 2011
    ..Therefore, UCB selection can prioritize matching, and better matched donors can be identified rapidly for most patients. This study is registered at http://clinicaltrials.gov as NCI clinical trial no. NCT00943800...
  10. doi request reprint High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML)
    Sarah M Larson
    Section of Hematology Oncology, University of Chicago Hospitals, Chicago, IL 60637, USA
    Leuk Lymphoma 53:445-50. 2012
    ..In this high risk AML population, HiDAC/MITO induction demonstrated an overall response rate of 55% with a low induction death rate of 9% and allowed 32 (41%) patients to proceed to allogeneic stem cell transplant...
  11. pmc Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation
    Andrew S Artz
    Section of Hematology Oncology, Department of Medicine, University of Chicago, the University of Chicago Cancer Research Center, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 14:1209-16. 2008
    ..These data require confirmation in non-T cell-depleted conditioning regimens. If validated, they suggest that preconditioning CRP holds promise for enhancing estimates of transplantation tolerance...
  12. doi request reprint Influence of related donor age on outcomes after peripheral blood stem cell transplantation
    Elie M Richa
    Biological Sciences Division, Department of Pathology, Section of Blood Bank and Transfusion Medicine, University of Chicago, Chicago, Illinois 60637, USA
    Cytotherapy 14:707-15. 2012
    ..The effect of related donor age for peripheral blood stem cell allografts (PBSC) on graft maintenance and outcomes, independent of CD34(+)cell dose, has not been well-characterized...
  13. pmc Allogeneic stem cell transplantation with alemtuzumab-based conditioning for patients with advanced chronic myelogenous leukemia
    Xavier Poiré
    Section of Hematology Oncology, Department of Medicine and the Cancer Research Center, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 50:85-91. 2009
    ..Disease recurrence is frequent but responds to DLI. In some cases, restoration of susceptibility to TKI was observed. Outcomes may improve with the routine administration of post-transplant TKI...
  14. pmc T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse
    Vaishalee P Kenkre
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA
    Leuk Lymphoma 52:214-22. 2011
    ..Our outcomes challenge the utility of the common practice of prophylactic DLI after T-depleted transplant for lymphoma...
  15. doi request reprint Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant
    Lucy A Godley
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Leuk Lymphoma 51:995-1006. 2010
    ..The remission induction of high-dose cytarabine and mitoxantrone for t-MN is a well-tolerated efficacious combination, which allows aggressive consolidation and long-term disease-free survival...
  16. doi request reprint Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products
    Melinda K Gordon
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, Chicago, IL, USA
    Leuk Lymphoma 49:531-7. 2008
    ..No patient has yet required transplantation. With median follow-up of 18 months, all patients remain in CCyR and 9 of 16 (54%) have undetectable BCR-ABL in the most recent blood and marrow sample...
  17. doi request reprint Phase I study of dose-escalated busulfan with fludarabine and alemtuzumab as conditioning for allogeneic hematopoietic stem cell transplant: reduced clearance at high doses and occurrence of late sinusoidal obstruction syndrome/veno-occlusive disease
    Peter H O'Donnell
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 51:2240-9. 2010
    ..This AUC is now being studied in phase II for patients receiving busulfan/fludarabine/alemtuzumab as alloHCT conditioning...
  18. ncbi request reprint Successful allogeneic transplantation of patients with suspected prior invasive mold infection
    Brian T Hill
    Department of Internal Medicine, Cancer Research Center, University of Chicago, IL, USA
    Leuk Lymphoma 48:1799-805. 2007
    ..We conclude that suspected prior invasive fungal infection should not preclude the use of allogeneic stem cell transplantation...
  19. doi request reprint Immune reconstitution after combined haploidentical and umbilical cord blood transplant
    Nitin Jain
    Section of Hematology Oncology, Department of Medicine, The University of Chicago Medical Center, Chicago, IL, USA
    Leuk Lymphoma 54:1242-9. 2013
    ..Overall, immune reconstitution after haplo-cord transplant is similar to that seen after cord blood transplant, despite infusion of much lower cord blood cell dose...
  20. ncbi request reprint Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation
    Andrew S Artz
    Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Biol Blood Marrow Transplant 12:954-64. 2006
    ..001) and enhanced prognostic power over the CCI alone (P = .018). Prospective studies evaluating more comprehensive functional and comorbidity measurements are warranted...
  21. pmc Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
    Hongtao Liu
    University of Chicago Medical Center 5841, S Maryland Ave, MC2115 Chicago, IL 60637, USA
    Haematologica 97:579-85. 2012
    ....
  22. pmc BK virus infection is associated with hematuria and renal impairment in recipients of allogeneic hematopoetic stem cell transplants
    Peter H O'Donnell
    Section of Hematology Oncology, Department of Medicine, The University of Chicago, 5841 S Maryland Avenue, Chicago, IL, 60637, USA
    Biol Blood Marrow Transplant 15:1038-1048.e1. 2009
    ..Investigation of whether prophylaxis against, or treatment of, BKV in the post-HSCT setting mitigates the associated morbidities, especially kidney injury, warrants prospective evaluation...
  23. doi request reprint Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia
    Olatoyosi M Odenike
    Section of Hematology Oncology, Department of Medicine, University of Chicago Medical Center, 5841 S Maryland Avenue, MC 2115, Chicago, IL 60637 1470, USA
    Invest New Drugs 26:233-9. 2008
    ..The primary objective of the study was to establish the maximum tolerated dose of 3-AP when given in combination with a fixed dose of cytarabine...
  24. pmc Paucity of HLA-identical unrelated donors for African-Americans with hematologic malignancies: the need for new donor options
    Alexander Dew
    Section of Hematology Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA
    Biol Blood Marrow Transplant 14:938-41. 2008
    ..To allow more African-American patients to proceed to transplant, innovative donor strategies, including adult cord blood transplantation, haploidentical transplant, or the identification of permissive mismatches should be investigated...
  25. doi request reprint Expanded indications for allogeneic stem cell transplantation in patients with myeloid malignancies
    Hongtao Liu
    Section of Hematology Oncology, University of Chicago, Chicago, Illinois 60637, USA
    Curr Opin Hematol 20:115-22. 2013
    ..Advancements in human leukocyte antigen (HLA) typing and supportive care have improved the risk-benefit ratio for SCT, expanding its indications...
  26. doi request reprint Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel
    Wendy Stock
    University of Chicago, Chicago, IL, USA
    Leuk Lymphoma 52:2237-53. 2011
    ..Whether or not the replacement of one dose of pegASNase for 6-9 doses of native ASNase can be achieved in adults with similar efficacy and acceptable toxicities to those achieved in children remains to be established...
  27. doi request reprint Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia
    Eunice S Wang
    Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Leuk Lymphoma 53:1543-51. 2012
    ..Eight/29 (28%) patients had decreased phosphorylated extracellular signal-regulated kinase (ERK)...
  28. ncbi request reprint Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies
    Todd M Zimmerman
    Department of Medicine, Section of Hematology Oncology, University of Chicago, Chicago, IL, USA
    J Clin Oncol 22:4816-22. 2004
    ..Tipifarnib, an orally bioavailable inhibitor of farnesyl transferase, has activity in hematologic malignancies, but the dose required to achieve the proposed biologic end point, inhibition of farnesylation, is unknown...
  29. doi request reprint Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet?
    Olatoyosi Odenike
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 38:196-214. 2011
    ....
  30. doi request reprint Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia
    Olatoyosi M Odenike
    Medicine Studies, University of Chicago, Chicago, Illinois, USA
    Clin Cancer Res 14:7095-101. 2008
    ..The primary objectives of the study were to evaluate the safety and efficacy of romidepsin in advanced AML...
  31. doi request reprint Burkitt lymphoma/leukemia: improving prognosis
    Vaishalee P Kenkre
    Section of Hematology Oncology, University of Chicago and the University of Chicago Cancer Research Center, Chicago IL 60637, USA
    Clin Lymphoma Myeloma 9:S231-8. 2009
    ....
  32. doi request reprint An integrated genomic approach to the assessment and treatment of acute myeloid leukemia
    Lucy A Godley
    Department of Medicine, The University of Chicago, Chicago, IL 60637, USA
    Semin Oncol 38:215-24. 2011
    ..With these expectations comes the hope that such an approach will lead to decreased toxicities and prolonged survival for patients...
  33. doi request reprint Progress in the treatment of adults with acute lymphoblastic leukemia
    Sarah Larson
    University of Chicago Medical Center and the University of Chicago Cancer Research Center, University of Chicago, Chicago, Illinois, USA
    Curr Opin Hematol 15:400-7. 2008
    ..However, the recent approach of adapting therapy according to biologic features appears to be resulting in significant progress for specific subsets of adults with acute lymphoblastic leukemia...
  34. ncbi request reprint Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem cells and posttransplantation interleukin-2 in relapsed or refractory non-Hodgkin lymphoma
    Koen Van Besien
    Section of Hematology Oncology, University of Illinois Chicago, 60637, USA
    Biol Blood Marrow Transplant 10:386-94. 2004
    ..Administration of IL-2-incubated peripheral blood stem cells and intensive posttransplantation IL-2 was associated with considerable but rapidly reversible toxicity. No effect on long-term outcome was observed...
  35. doi request reprint Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults
    Ryan Mattison
    Section of Hematology Oncology, University of Chicago Medical Center, 5841 South Maryland, Chicago, IL 60637, USA
    Curr Hematol Malig Rep 3:144-51. 2008
    ..Assessing the outcomes in adult and pediatric clinical trials that enroll adolescents and young adults can be especially useful in determining how best to treat these patients. Current new treatment strategies are also discussed...
  36. ncbi request reprint Assaying Bcr-Abl kinase activity and inhibition in whole cell extracts by phosphorylation of substrates immobilized on agarose beads
    Ding Wu
    Center for Molecular Oncology and Department of Molecular Genetics and Cell Biology, University of Chicago, IL 60637, USA
    Anal Biochem 347:67-76. 2005
    ..This simple kinase assay is sufficiently straightforward and robust for use in clinical laboratories and is potentially adaptable to high-throughput assay formats...
  37. doi request reprint A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia
    Rebecca B Klisovic
    Division of Hematology and Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
    Clin Cancer Res 14:2444-9. 2008
    ..This phase I study was conducted to determine a biologically effective dose and describe the safety of MG98 in MDS/AML...
  38. ncbi request reprint Progressive transformation of germinal centers. Report of 2 cases and review of the literature
    Amit Verma
    Section of Hematology Oncology, University of Illinois at Chicago, 60607, USA
    Acta Haematol 108:33-8. 2002
    ..Here, we describe two cases of this disease and review the literature on the association of PTGC with lymphocyte-predominant Hodgkin's disease...
  39. doi request reprint Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia
    Syed A Abutalib
    Section of Hematology and Oncology, Cancer Treatment Centers of America, Zion, IL, USA
    Hematol Oncol Clin North Am 23:1099-119, vii. 2009
    ..Looking toward the future, the authors highlight several of the new therapeutic agents and discuss some of the recently described molecular genetic aberrations that might serve as therapeutic targets for future drug development...
  40. ncbi request reprint Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
    Wendy Stock
    Leukemia Program, Section of Hematology Oncology, Department of Medicine, The University of Chicago Division of Biological Sciences, Chicago, IL, USA
    Clin Adv Hematol Oncol 6:487-8. 2008
  41. ncbi request reprint Minimal residual disease: current status in leukemia
    Wendy Stock
    University of Chicago, USA
    Clin Adv Hematol Oncol 1:210-1. 2003
  42. ncbi request reprint Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia
    Steven M Devine
    Blood and Marrow Transplantation Program, Section of Hematology Oncology, University of Illinois College of Medicine, 840 South Wood Street, M C 787, Chicago, IL 60612, USA
    Blood 99:2255-8. 2002
    ..These results support the feasibility and effectiveness of reduced-intensity conditioning prior to allogeneic HSC transplantation for older patients with advanced MMM...
  43. ncbi request reprint Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013
    Richard T Silver
    Weill Medical College of Cornell University, Division of Hematology Oncology, 525 E 68th St Box 581, New York, NY 10021, USA
    Leuk Lymphoma 44:39-48. 2003
    ..01) using a landmark analysis at 18 months. This intermittent schedule of rIFNalpha-2b/ara-C has a high response rate in patients with CML with acceptable toxicity...
  44. ncbi request reprint Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia
    Steven D Gore
    The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Am J Hematol 79:119-27. 2005
    ..However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL...
  45. ncbi request reprint A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse
    Joseph Moore
    Duke University Medical Center, Morris Cancer Clinics, P O Box 3872, Durham, NC 27710, United States
    Leuk Res 30:777-83. 2006
    ..Serious adverse events for the oblimersen/GO combination were qualitatively similar to those reported for GO alone. Oblimersen can be safely combined with GO. Assessment of incremental benefit will require a randomized trial...
  46. ncbi request reprint Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity
    Guido Marcucci
    Division of Hematology Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA
    J Clin Oncol 23:3404-11. 2005
    ..Herein, we investigated the feasibility of this approach in untreated elderly AML patients by administering oblimersen sodium (G3139), an 18-mer phosphorothioate antisense to Bcl-2, during induction and consolidation treatments...
  47. pmc Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    Timothy Hughes
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 108:28-37. 2006
    ..We recognize that our recommendations are provisional and will require revision as new evidence emerges...
  48. ncbi request reprint Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection
    Koen Van Besien
    Blood 103:4373-4. 2004
  49. doi request reprint A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
    David A Rizzieri
    Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:2756-62. 2008
    ..A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies...
  50. pmc Gene expression changes associated with progression and response in chronic myeloid leukemia
    Jerald P Radich
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Proc Natl Acad Sci U S A 103:2794-9. 2006
    ..These studies point to specific gene pathways that might be exploited for both prognostic indicators as well as new targets for therapy...